Novartis: gains positive opinion for new cholesterol drug

(CercleFinance.com) - Novartis has received a positive opinion for Leqvio, its new treatment of high cholesterol, from the European Medicines Agency's Committee for Medicinal Products for Human Use, paving the way for potential approval of the drug.


Leqvio has a new mechanism of action which delivers sustained low-density lipoprotein cholesterol (LDL-C) reduction for patients with atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia, a major driver of heart attacks and strokes.

The European Commission generally follows the recommendations made by the CHMP.

Copyright (c) 2020 CercleFinance.com. All rights reserved.